BRAF and non-small cell lung carcinoma: The tolerability profiles in this phase I study have been seen in subsequent placebo-controlled, phase II trials of selumetinib plus dacarbazine in patients with treatment-naïve BRAF-mutant metastatic melanoma and selumetinib plus docetaxel in pretreated patients with KRAS-mutant advanced NSCLC [12, 13].